Neuroprotective Mechanisms as Treatment Strategy in Alzheimers disease

Author(s): Agneta Nordberg

Journal Name: Current Medicinal Chemistry - Central Nervous System Agents
Continued as Central Nervous System Agents in Medicinal Chemistry

Volume 1 , Issue 3 , 2001


Alzheimers disease is the most common dementia disorder characterised by a progressive loss of cognitive function. The major neuropathological hallmark for the disease is the presence of beta amyoloid (Aβ) in the brain. The research to date indicates there are multiple factors that can trigger the development of Alzheimers disease. Therefore there are at present several tentative treatment strategies being tested experimentally and clinically. Symptomatic treatment with cholinesterase inhibitors is typically used currently for treatment of Alzheimers disease. New treatment strategies having neuroprotective effects aim to influence the course of the disease and preventing or reducing Aβ accumulation in the brain. This review covers recent findings regarding the experimental and clinical experience with Alzheimers treatments utilizing growth factors, anti-inflammatory drugs, anti-oxidantia, estrogens, cholinergic agonists and anti-amyloid substances.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2001
Published on: 01 March, 2012
Page: [239 - 246]
Pages: 8
DOI: 10.2174/1568015013358464
Price: $65

Article Metrics

PDF: 1